In conclusion, while HER-2/neu shows considerable promise as both a diagnostic and therapeutic target, ongoing and expansive research is crucial to unlocking its full potential in improving patient outcomes in cervical carcinoma. This evidence concerns the gene ERBB2 and cervical carcinoma.